In addition, the additive anti-proliferative activity of Danusertib and IM was also found in primary CD34+ cells derived from CML patients, including the immature CD34+38− subpopulation which has been demonstrated to contain quiescent leukemic stem cells [32], [33]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.